Yin D P, Sankary H N, Williams J, Krieger N, Fathman C G
Department of Surgery, Stanford University School of Medicine, California 94305, USA.
Transplantation. 1996 Dec 15;62(11):1537-9. doi: 10.1097/00007890-199612150-00001.
This study was designed to investigate the effectiveness of combined perioperative anti-CD4 and human (h)CTLA4Ig therapy in preventing allorejection of small bowel transplantation in high-responder Lewis rat recipients of ACI grafts. Anti-CD4 (5 mg/kg x 4 days) or hCTLA4Ig (0.5 mg/rat x 2 days) therapy alone delayed, but did not prevent, allograft rejection after small bowel transplantation of ACI into Lewis rats. All grafts were rejected in 18 and 10 days, respectively. However, a regimen of anti-CD4 (5 mg/kg x 4 days) combined with hCTLA4Ig (0.5 mg/rat x 2 days) allowed indefinite survival of ACI small bowel allografts. Second donor-matched heart grafts were permanently accepted, whereas third-party (Sprague-Dawley) heart allografts were rejected by the tolerant recipients. These data suggest that these two reagents produced a synergistic effect in preventing allorejection of small bowel transplantation.
本研究旨在探讨围手术期联合应用抗CD4和人（h）CTLA4Ig疗法在预防高反应性Lewis大鼠接受ACI移植物的小肠移植同种异体排斥反应中的有效性。单独使用抗CD4（5mg/kg×4天）或hCTLA4Ig（0.5mg/只大鼠×2天）疗法可延迟，但不能预防ACI小肠移植到Lewis大鼠后的同种异体移植排斥反应。所有移植物分别在18天和10天被排斥。然而，抗CD4（5mg/kg×4天）联合hCTLA4Ig（0.5mg/只大鼠×2天）的方案可使ACI小肠同种异体移植物无限期存活。第二次供体匹配的心脏移植物被永久接受，而第三方（Sprague-Dawley）心脏同种异体移植物被耐受的受体排斥。这些数据表明，这两种试剂在预防小肠移植的同种异体排斥反应中产生了协同作用。
